|
|
Profile
|
Delegates :
Yuji Otsuki |
|
Incorporated :
May 30 , 2022 |
Paid in Capital :
60 Million yen |
Employees :
5 人 |
Address :
Fujimi Duplex B's 4F 1 -3-11 Fujimi, Chiyoda-ku TOKYO
〒1020071
|
TEL/FAX :
/ |
URL：
https://ferroptocure.com |
Attachment :
|
Mission/Background :
FerroptoCure Inc, is developing anticancer drugs utilizing ferroptosis. Ferroptosis is cell death caused by oxidative stress, and in the cancer field, it has been shown that the suppression of ferroptosis is related to the occurrence and proliferation of cancer. Furthermore, in recent years, it has also attracted attention as a mechanism for acquiring resistance to anticancer drugs in various types of cancer. Therefore, anticancer drugs targeting this mechanism are expected to be effective against a wide range of cancer types with unprecedented high efficacy. We have already started Phase I clinical trials and aim to create anticancer drugs that overcome the suppression of ferroptosis, bringing significant innovation to current cancer treatment. |
|
Technology & Business
|
In recent years, interest has grown in the anti-oxidative systems in cancer cells, which prevent cell death caused by oxidative stress (ferroptosis). These systems aid cancer cell survival and treatment resistance. Our company has developed the first anti-cancer drugs targeting this mechanism and is conducting Phase 1 clinical trials for triple-negative breast cancer. Our drugs have shown anti-tumor effects in various cancers and hold great promise. Using low molecular weight compounds, our approach avoids the need for costly techniques like cell therapy or antibody drugs, offering safe, effective, and convenient therapy for patients with inoperable or recurrent tumors. This simple and safe approach can be widely offered worldwide, including in developing countries, reaching those in need of effective treatments.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
FC001
|
Phase1
|
Ferroptosis inducing anti-cancer treatment targeting Triple negative breast cancer
|
Completion of Phase1
|
FC002
|
Preclinical
|
Ferroptosis inducing anti-cancer treatment targeting Solid cancer
|
Phase1
|
FC003
|
Discovery
|
Ferroptosis inducing anti-cancer treatment targeting Triple negative breast cancer
|
Preclinical
|
|
|
|
|
|
|
|
|
|
Highlights
|
・May2023 Fundraising of Seed Round
https://prtimes.jp/main/html/rd/p/000000001.000122662.html
・January2024 Phase1 of FC001
https://www.ncc.go.jp/jp/ncce/division/clinical_trial/ctas/patient/list/multiple/1363.html
|
|
Alliance strategy
|
FerroptoCure is searching pharmaceutical companies who can collaborate to codevelop or be licensed-in.
FerroptoCure is also searching VCｓ and companies who can invest us.
|
|
|